Thus, these results demonstrate that cisplatin depletes tumor cells lacking NANOG while enriching tumor cells containing NANOG, suggesting that NANOG expression in tumor cells could confer a survival advantage under the selection pressure imposed by cisplatin. This evidence concerns the gene NANOG and neoplasm.